自1982年以来,我国血源性乙型肝炎(简称乙肝)疫苗和基因工程乙肝疫苗先后进入大规模生产。经过数亿新生儿、婴幼儿等人群的使用证明,两种乙肝疫苗的安全性和免疫原性均优。据在广西农村地区不筛选母亲,新生儿乙肝疫苗接种率达到85％以上,儿童血源性乙肝疫苗免后13～15年效果的观察,免疫后HBsAg阳性率已从16％下降至2％以下,抗体水平虽明 Since 1982, China’s blood-borne hepatitis B (referred to as hepatitis B) vaccine and genetic engineering hepatitis B vaccine has entered mass production. After hundreds of millions of newborns, infants and young children, the use of the crowd proved that the safety and immunogenicity of both hepatitis B vaccines are excellent. According to the observation that no screening of mothers in rural areas of Guangxi, neonatal hepatitis B vaccine coverage rate of 85% or more, blood-borne hepatitis B vaccine in children after 13 to 15 years of observation, after immunization HBsAg-positive rate decreased from 16% to 2% or less Although the antibody level is clear